105102-22-5
105102-22-5
Chemical Structure
Mometasone
- CAS No.: 105102-22-5
- Formula:C22H28Cl2O4
- Molecular Weight:427.36
IUPAC Name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: QLIIKPVHVRXHRI-CXSFZGCWSA-N
SMILES: Cl[C@@]1([C@]2(C=C3)C)[C@](CCC2=CC3=O)([H])[C@@](C[C@@H](C)[C@]4(O)C(CCl)=O)([H])[C@]4(C)C[C@@H]1O
Biological Activity: Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mometasone | 99.46% | Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mometasone (Standard) | 99.72% | Mometasone (Standard) is the analytical standard of Mometasone. This product is intended for research and analytical applications. Mometasone is an inhaled glucocorticoid. Mometasone can be used in mild asthma with a low sputum eosinophil level. Mometasone has the potential for the research of chronic hand eczema and rhinosinusitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mometasone-d5 | Mometasone-d5 is the deuterium labeled Mometasone. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Veien NK, et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999 May;140(5):882-6. [Content Brief]
- [2]. Lazarus SC, et al. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. N Engl J Med. 2019 May 23;380(21):2009-2019. [Content Brief]
